Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 413 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Naltrexone Clear all
Completed Phase 4 Interventional

Biomarkers of Injectable Extended Release Naltrexone Treatment

NCT02324725
View directory record Official record
Conditions
Heroin Dependence, Opioid Dependence
Interventions
Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 3 Interventional

Combined Pharmacotherapies for Alcoholism

NCT00768508
View directory record Official record
Conditions
Alcoholism
Interventions
Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy, Naltrexone 50 mg/day + Cognitive Behavioral Therapy, Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy, Placebo + Cognitive Behavioral Therapy
Drug · Other
Lead sponsor
Bankole Johnson
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Project STAMINA (Syringe Service Telemedicine Access for Medication-assisted Intervention Through NAvigation)

NCT04575324
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Telemedicine Linkage Intervention
Behavioral
Lead sponsor
Chestnut Health Systems
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 3, 2026, 9:44 AM EDT
Withdrawn Phase 2 Interventional

Neurobiology of Opioid Dependence: 5 - 5

NCT00000196
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone
Drug
Lead sponsor
Yale University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1998
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

NCT02735603
View directory record Official record
Conditions
Heart Repolarization
Interventions
Naltrexone HCl/bupropion HCl, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

NCT02259179
View directory record Official record
Conditions
Healthy
Interventions
Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 3, 2026, 9:44 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

NCT06500793
View directory record Official record
Conditions
Pharmacokinetics, Healthy Volunteer
Interventions
PF614 capsule, Nafamostat Mesylate
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Depot Naltrexone Treatment of Opioid Dependent Parolees

NCT00756990
View directory record Official record
Conditions
Opioid Dependence
Interventions
Depot Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact on Opioid Use of Bundling Medication-assisted Treatment With mHealth

NCT02712034
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
MAT + A-CHESS, MAT
Behavioral · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

NCT00711477
View directory record Official record
Conditions
Obesity
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, fMRI scan
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Upton, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Sep 3, 2026, 9:44 AM EDT
Terminated Phase 2 Interventional Results available

Low-dose Naltrexone for Bladder Pain Syndrome

NCT04450316
View directory record Official record
Conditions
Bladder Pain Syndrome, Interstitial Cystitis
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

Naltrexone and Memantine Effects on Alcohol Drinking Behaviors

NCT01519063
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Naltrexone and memantine first, Naltrexone and Placebo first
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study for Naltrexone on the Abuse Potential of Methylphenidate

NCT03769064
View directory record Official record
Conditions
Naltrexone, Methylphenidate Abuse
Interventions
Placebo, Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134, Treatment Phase Sequence 1342, Treatment Phase Sequence 3421
Drug
Lead sponsor
Avekshan LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 3, 2026, 9:44 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease

NCT01810185
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Low dose naltrexone, Placebo
Drug
Lead sponsor
Santa Barbara Cottage Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

Double-Blind Naltrexone in Compulsive Sexual Behavior

NCT00467558
View directory record Official record
Conditions
Compulsive Sexual Behavior
Interventions
Naltrexone, Sugar pill
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neuropharmacological Basis of Social Connection: The Role of Opioids

NCT01672723
View directory record Official record
Conditions
Psychology, Social
Interventions
Naltrexone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 3 Interventional

A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone

NCT00501696
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
4.5 mg Naltrexone, Naltrexone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 86 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 18, 2008 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Results available

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

NCT00420992
View directory record Official record
Conditions
Osteoarthritis, Chronic Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 3, 2026, 9:44 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers

NCT07064564
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone implant, 14.4 grams, Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg
Drug
Lead sponsor
Akyso Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 4 Interventional Results available

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

NCT02032433
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Extended-Release Naltrexone, Buprenorphine-Naloxone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Tarzana, California • Jacksonville, Florida • Rockville, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Drug Treatment for Pathologic Gambling Disorder

NCT00053677
View directory record Official record
Conditions
Gambling
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 3, 2026, 9:44 AM EDT
Not listed Phase 3 Interventional

Self-Injury: Diagnosis and Treatment

NCT00065936
View directory record Official record
Conditions
Self-Injurious Behavior, Mental Retardation
Interventions
Naltrexone hydrochloride, Transcutaneous sensory nerve stimulation
Drug · Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
4 Years to 25 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Morganton, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 3, 2026, 9:44 AM EDT
Withdrawn Not applicable Interventional

Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).

NCT00675532
View directory record Official record
Conditions
Drug Dependence
Interventions
Primary Care Counseling, Cognitive-behavioral psychotherapy
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 3, 2026, 9:44 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Comparison of Three Opioid Detoxification Treatment Regimens

NCT03678792
View directory record Official record
Conditions
Opioid-Related Disorders, Opioid Withdrawal
Interventions
Buprenorphine/naloxone, Morphine, Tramadol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Sep 3, 2026, 9:44 AM EDT